Cost-effectiveness of omalizumab for the treatment of chronic spontaneous urticaria.

Published in: The British journal of dermatology (2018)

Omalizumab is cost-effective compared with SoC. The outcomes of this study were used to establish omalizumab as third-line therapy in the Dutch treatment guidelines for CSU.

Keyphrases

stem cells
type diabetes
metabolic syndrome
bone marrow
insulin resistance
replacement therapy